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We appreciate the opportunity to reply to this interesting work
by Drs Ghilardi and Biondi regarding our article.1 We utilized gene
microarray analysis to compare aneurysmal, occlusive, and control
tissue from human aorta. We found a difference in MMP expres-
sion only in MMP-9 out of 16 different MMPs evaluated. MMP-3
values were not significantly different between the three groups,
but interestingly, the highest values were in the control group.
These investigators have identified a potential association be-
tween a polymorphism in the MMP-3 gene promoter and AOD.
The importance of this genetic polymorphism to the pathophysi-
ology of AOD remains to be established. Nevertheless, the findings
raise a number of questions and identify several areas of future
investigation.
Although statistically significant, the association between
AOD and the 6A/6A polymorphism is not particularly robust.
Less than half of the AOD patients exhibit this polymorphism. The
frequency of homozygosity for this polymorphism in AOD pa-
tients is only 60% higher than controls (47% of AOD patients
versus 29% of control patients). Thus, this MMP-3 polymorphism
might contribute to the AOD phenotype in some, but not all,
patients. There could exist other genetic polymorphisms or envi-
ronmental factors that cooperate with this MMP-3 genotype to
produce the AOD phenotype, but there is no information at the
present time to suggest such a mechanism.
It is possible this polymorphism produces subtle differences in
MMP-3 expression that cannot be detected by gene microarray
analysis, which in most cases can reliably detect changes of two-
fold or greater. The fact that not all AOD patients display the
6A/6A genotype further reduces the likelihood that a difference in
expression would be detected by gene microarray analyses that
average expression data within groups of patients. This illustrates a
potential weakness of large-scale gene microarray analyses, which
are not suited to identifying small changes or changes that are
variable within a study group. In this regard, it would be informa-
tive to compare MMP-3 expression levels in AOD and control
patients with 5A/5A and 6A/6A genotypes. This could establish
the physiologic effect of the promoter genotype on MMP-3 ex-
pression in a physiologic setting and provide information on rela-
tive differences in MMP-3 expression between AOD and aortic
control tissue.
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